Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 55,500 |
|
|||||
| News | - | ||||||
| Day High | 0.039 | Low High |
|||||
| Day Low | 0.0371 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oncotelic Therapeutics Inc (QB) | OTLC | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.0019 | -4.87% | 0.0371 | 15:30:11 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.039 | 0.0371 | 0.039 | 0.0371 | 0.039 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6 | 55,500 | US$ 0.037714 | US$ 2,093 | - | 0.01 - 0.05 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 14:36:43 | 22,000 | US$ 0.0371 | USD |
Oncotelic Therapeutics Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 15.97M | 395.84M | 174.23M | 70k | -7.9M | -0.02 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Oncotelic Therapeutics (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/02/2024 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/30/2023 | 08:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/23/2023 | 09:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/18/2023 | 16:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 7/13/2023 | 08:25 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities |
| 7/13/2023 | 08:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 6/30/2023 | 08:25 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OTLC Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.03655 | 0.039 | 0.0361 | 0.0375151 | 115,282 | 0.00055 | 1.50% |
| 1 Month | 0.0376 | 0.04 | 0.0352 | 0.0374653 | 76,095 | -0.0005 | -1.33% |
| 3 Months | 0.0395 | 0.044 | 0.033 | 0.0387346 | 65,363 | -0.0024 | -6.08% |
| 6 Months | 0.0435 | 0.045 | 0.0301 | 0.0390622 | 69,671 | -0.0064 | -14.71% |
| 1 Year | 0.034 | 0.05 | 0.01 | 0.0303689 | 149,169 | 0.0031 | 9.12% |
| 3 Years | 0.295 | 0.2975 | 0.01 | 0.0980215 | 176,911 | -0.2579 | -87.42% |
| 5 Years | 0.24 | 0.36 | 0.01 | 0.1103199 | 178,577 | -0.2029 | -84.54% |
Oncotelic Therapeutics (QB) Description
| Oncotelic Therapeutics, Inc. (OTLC) are developing three lines of therapeutics. 1) Oncology/Virology - we are developing OT-101 (TGF-beta antisense/ Artemisinin) and VDA agents (Oxi4503/CA4P) against viral infections and various tumors including three rare pediatric tumors (DIPG, Melanoma, and AML). The program is being funded by our partner GMP through a JV that we are intend to take IPO. 2) AL-101 (intranasal-apomorphine) for the treatment of Parkinson Disease, Erectile Dysfunction not responding to PDE5 inhibitor, and Female Sexual Dysfunction. 3) Animal health product including oncology (CA4P and Artemishas). |
